JD vs. CRSP

In the year-to-date period, JD achieves a -3.46% return, which is significantly lower than CRSP's -2.77% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for JD.com, Inc. (JD) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current JD Sharpe Ratio is 0.40, which is higher than the CRSP Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of JD and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

JD's dividend yield for the trailing twelve months is around 3.01%, while CRSP has not paid dividends to shareholders.

The maximum JD drawdown since its inception was -79.14%, smaller than the maximum CRSP drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for JD and CRSP. For additional features, visit the drawdowns tool.

The current volatility for JD.com, Inc. (JD) is 15.43%, while CRISPR Therapeutics AG (CRSP) has a volatility of 22.51%. This indicates that JD experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between JD.com, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.